avantium

Initial Public Offering of Avantium N.V.

Pioneering renewable chemicals company, developing innovative sustainable chemistry solutions to commercial reality

We list the main features for you at a glance:

- Avantium aims to develop ground-breaking **proprietary chemical technologies** and production processes to convert **biobased feedstock** into **high-performing**, **cost-competitive** and sustainable products, together with its **partners around the world**. Avantium also provides **advanced catalysis research and development services** and systems to renowned chemical, refinery and energy companies.
- Avantium's market opportunity is driven by the increasing demand for renewable chemicals. Today, the **chemical industry is still heavily dependent on fossil resources.** Growing demand, limited reserves and price volatility of fossil resources, climate change concerns and tightening regulations are drivers for **a transition towards more sustainable chemistry**.
- Avantium has developed the proprietary **YXY technology that converts plant-based sugars into FDCA, a key building block for producing polyesters, such as PEF**, and listed by the US Department of Energy **as #2 in Top-12 value added chemicals for establishing the "green" chemistry industry of the future.**
- PEF is a **100% bio-based**, fully recyclable plastic with **superior performance** properties compared to today's most widely used plastics like petroleum-based PET, making it an attractive **alternative to PET** and other packaging materials such as aluminium, glass, cartons. On an industrial scale, PEF offers a cost-effective solution for applications ranging from **bottles to packaging film and fibres**, positioning it to become the **next generation packaging material**, having a **>€200bn market potential**.
- In November 2016, Avantium established **the Synvina joint venture with BASF,** the global #1 chemical company, to commercialise the YXY Technology. Synvina intends to build **a first commercial scale plant for the production of FDCA in Antwerp**. Synvina will further develop the business collaborations formed over the last years with over **20 partners, including The Coca-Cola Company, Danone, ALPLA and Mitsui & Co. Ltd.**
- The YXY Technology is the furthest advanced technology developed by Avantium's Renewable Chemistries business. Two other projects have reached or are entering pilot plant stage and are expected to enter commercial stage in 2017-2020: **Project Zambezi** and **Project Mekong.** Seven additional Renewable Chemistry projects are currently under development, of which two are at concept stage and five are at lab stage.
- Avantium's historical business, Catalysis, has been providing **advanced catalysis R&D** services and systems to companies in the chemical, refinery and energy sector for over 15 years. The Group has developed a **strong, international customer base** including several industry leaders.

Additional information or subscription details can be obtained from:

Your KBC Bank branch, the KBC website and the KBC Team

Prospective investors should be able to bear the economic risk of an investment in the Offered Shares and should be able to sustain a partial or total loss of their investment. An investment in the Offered Shares involves substantial risks and uncertainties. Prospective investors should read the entire Prospectus before investing in the Offered Shares, and, in particular, should review elements D.1 and D.3 of the "Summary" beginning on page 6 and "Risk factors" beginning on page 52 for a discussion of certain factors that should be considered in connection with an investment in the Offered Shares.
All of these factors should be considered before investing in the Offered Shares.The Prospectus is available free of charge from your KBC Bank branch, the KBC Team (+32 (0)16 43 29 15) or via www.kbc.be/avantium. The Prospectus is available in English. The summary of the Prospectus has been translated in Dutch and French.

Is this something for you?

Product rating:

Along with the volatility of the market, this product rating, developed by KBC, also takes other factors into account such as scheduled repayment of capital, credit worthiness, asset allocation, exposure to foreign currencies and liquidity. You can find more information under "Product Rating".

Client risk profile:

This product focuses in the first place on investors with a very dynamic profile. We recommend you to only invest in this product if you understand the essential characteristics of the product and more specifically if you understand what risks are associated with this product.

In case you wish to buy this product outside the context of investment advice , the bank must determine whether you have sufficient knowledge and experience in relation to the product. If this is not the case, the bank has to warn you that the product is not appropriate for you. If the bank offers the product in the context of investment advice, the bank must ascertain whether the product is suitable for you, taking into account your knowledge and experience in relation to the product, your investment goals and your financial capacity. Ask you KBC adviser for advice.

For the complete overview of customer risk profiles, go to www.kbc.be/riskprofile.**www.kbc.be/riskprofile**.

About Avantium

Leading YXY Technology product, PEF, strongly positioned to become next-generation packaging material

PEF is a 100% biobased, 100% recyclable plastic with superior performance properties compared to today's plastics packaging materials that are made from petroleum:

- PEF has superior barrier properties compared to PET for gases like carbon dioxide and oxygen, leading to longer-lasting carbonated drinks and longer shelf life of packaged products.
- PEF offers a higher mechanical strength than PET, allowing for increasing shaping possibilities and thinner PEF packaging
- In terms of thermal properties, PEF is considered more attractive than PET due to its superior ability to withstand heat and its ability to be processed at lower temperatures
- Furthermore, PEF can offer a significant reduced carbon footprint compared to PET at industrial scale. The production of PEF could reduce carbon (CO2) emissions and non-renewable energy use by 50-70% compared to PET.

These properties make PEF an attractive alternative to PET and other packaging materials such as aluminium, glass, cartons. Illustratively, the end markets for these packaging materials represent an aggregate annual turnover of over US$200 billion. On an industrial scale, PEF offers a cost-effective solution for applications ranging from bottles to packaging film and in the long term also fibres (for i.e. clothing, carpets, and car tires).

Market opportunity: The shift from fossil-based to renewable materials is especially relevant in the plastics industry



Plastics have substantial benefits including low weight, low costs and high performance. The plastics industry is however highly reliant on petroleum and gas, which make up more than 90% of its feedstock.

To reduce this dependency on fossil resources and related CO2 emission, the plastics industry must decouple the production of plastics from fossil feedstock and accelerate the transition to cost and performance competitive biobased plastics.

JV with BASF, the global #1 chemical company, to commercialise YXY

In November 2016, Avantium established a 49:51 joint venture (Synvina) with BASF to commercialise the YXY Technology. **Synvina intends to build and operate in Antwerp the first commercial scale plant (the "Reference Plant") for the production of FDCA (an investment of €275-325m). The construction of the Reference plant is expected to start by the end of 2018, with sales of FDCA and PEF expected to commence in 2021.** Synvina intends to subsequently license the YXY Technology to BASF and others to enable global industrial scale production of FDCA and PEF as from 2021.

Synvina intends to be the first to commercialise PEF as a game-changing material used in packaging, fibres and other PEF applications with the support of partners such as The Coca-Cola Company, Danone, ALPLA and Mitsui.

Promising Renewable Chemistries projects, with two projects expected to enter commercial stage in 2017-2020



Renewable Chemistries is Avantium's development division with a portfolio of new projects focusing on the conversion of biomass to chemical building blocks and plastic materials. It has nine projects in development of which Project Mekong and Project Zambezi are the most advanced.

Project Zambesi is a cost-effective process for the production of high-purity glucose from non-food biomass that can be converted into bio chemicals such as FDCA. In February 2017, Avantium announced a non-binding partnership with AkzoNobel, RWE and Staatsbosbeheer to develop a flagship biorefinery.

Project Mekong is a one-step process for the production of MEG from glucose. Today's market for MEG is predominantly fossil-based and represents an annual turnover of over US$20 billion. Currently, approximately 1% of the MEG production is bio-based as a premium of 30-35% exists for bio-MEG.

Catalysis – 15 years proven track record supplying superior systems&services to global oil & chemical majors

For over 15 years, Catalysis has been providing advanced catalysis R&D services and systems to companies in the chemical, refinery and energy sector. Although the costs of a catalyst are relatively minimal, the impact of the performance on the chemical process is crucial to the economic performance of large chemical or refinery plants around the world.

Avantium helps its strong, international customer base to innovate faster with a higher probability of success and to shorten the time-to-market of new catalysts.

Avantium gained considerable experience and expertise from its Catalysis business and has (co-)invented numerous new catalysts and new and improved chemical processes for its customers.

A description of the risks related to the industry and the business of Avantium can be found on page 5- 6 of this document.

Features

ISSUER	Avantium N.V. (a public company with limited liability incorporated under Dutch law, with its corporate seat in Amsterdam, The Netherlands) (the "Company")
ISIN CODE	NL0012047823
SYNDICATE	Joint Global Coordinators: KBC Securities and ING. Joint Global Bookrunners: KBC Securities, ING and Rabobank Co-lead manager: Oddo.
ROLE OF KBC BANK NV	Selling Agent
CURRENCY	EUR
OFFERING	The Company is offering up to 8.133.168 newly issued ordinary shares (the "New Offer Shares"). The Company may, in common agreement with the Joint Global Coordinators, increase the total number of New Offer Shares by up to 15%, up to a maximum of 9.353.143 New Offer Shares (the "Increase Option" and the "Increase shares"). Any decision to exercise the Increase Option will be communicated, at the latest, on the date of the announcement of the results of the offering. ING (the "Stabilisation Agent"), acting on behalf of the Syndicate is expected to be granted by the Company an over-allotment option which entitles the Stabilisation Agent, acting on behalf of and in agreement with the Syndicate, to subscribe to additional new shares in an aggregate amount equal to up to 15% of the New Offer Shares allocated in the Offering at the Offer Price to cover short positions from any over-allotments made in connection with the Offering (the "Over-Allotment Option" and the "Over-Allotment shares"). Participants of the Company's option plan are holders of depositary receipts for ordinary shares in the Company, issued by Stichting Administratiekantoor Avantium (the "Avantium Foundation"). The Avantium Foundation is offering 48,650 Shares (the "Management Shares") on behalf of the Company's CEO, CFO and CTO (the "Managers"), representing 0.6% of the Offer Shares (excluding the Increase Option and Over-Allotment). They will be receiving proceeds through the sale of the Management Shares to repay or compensate for financing and related costs incurred in 2007 in connection with their investment in these Shares. The term New Offer Shares includes, unless the context indicates otherwise, the Increase Shares and the Over-Allotment Shares. The term Offer Shares includes the New Offer Shares and the Management Shares. The minimum net proceeds of the Offering for the Company must be at least €65 million, otherwise the Offering shall be cancelled. The Offering consists of: (i) a public offering in the Netherlands and Belgium to institutional and retail investors and (ii) private placements to certain institutional investors in various other jurisdictions outside the United States in reliance on Regulation S (Regulation S) under the US Securities Act of 1933, as amended. . The results of the Offering will be stated in the offering statement that will be published, ultimately on the first trading day following the end of the Offering Period, through a press release that will also be posted on the Company's website (the "Offering Statement").
PRE-COMMITMENT	The Company has received (i) unconditional and irrevocable commitments to participate in the Offering and subscribe for Offer Shares from all Convertible Loan Lenders (amongst whom PMV, FPIM, Sofinnova, Capricorn and others) for an aggregate amount of €20 million and (ii) firm intentions to participate in the Offering and to subscribe for Offer Shares from certain other investors for an aggregate amount of €44 million (those investors together with the Convertible Loan Lenders, named the "Cornerstone Investors"). These Cornerstone Investors will be fully allocated the amounts for which the Company received commitments or intentions to subscribe. Each Cornerstone Investor who will subscribe for Offer Shares for at least €5 million will receive one warrant for every four Offer Shares subscribed for in connection with its irrevocable commitmint or firm intention, entitling it to acquire one Share per warrant for an exercise price of 125% of the Offer Price (the "Warrants"). The Cornerstone Investors will receive a total number of 1.249.998 Warrants, assuming all commitments and firm intentions result in the allocation of Offer Shares to the Cornerstone Investors. The Warrants will mature

	five years following the Settlement Date and are exercisable after two years following the Settlement Date. The Warrants shall not be listed on any stock exchange.
OFFER PRICE	The Offer Price: 11.00 euros per Offer Share ("Offer Price"). A supplement to the Prospectus will be published in the event the Offer Price is changed. The results of the Offering will be stated in the offering statement that will be published, ultimately on the first trading day following the end of the Offering Period, through a press release that will also be posted on the Company's website (the "Pricing Statement").
OFFERING PERIOD	The Offering will take place from 9.00 Central European Time (CET) on 6 March 2017 until 13 March 2017 CET on 17.30 (the "Offering Period"), subject to acceleration or extension of the timetable for the Offering, provided that the Offering Period shall be at least six business days.
RIGHT TO WITHDRAW	In the event of the publication of a supplement to the Prospectus, the retail investors will have the right to withdraw their orders made prior to the publication of the supplement. However in this transaction, retail investors in Belgium are also entitled to cancel or amend their application, at the financial intermediary where their original application was submitted, at any time prior to the end of the Offering Period (i.e 5:30pm on 13 march 2017). Without prejudice to the foregoing, the retail investors in Belgium that have placed subscription orders through the KBC Bank branch, the KBC Team (+32 (0)16 43 29 15) or via www.kbc.be/avantium should contact the KBC team (+32 (0)16 43 29 15), should they wish to cancel or amend their subscription order.
ALLOCATION	Allocation of the Offer Shares to investors will be determined at the end of the Offering Period by the Company in common agreement with the Joint Global Coordinators on the basis of the respective demand of both retail investors and institutional investors and on the quantitative, and, for institutional investors only, the qualitative analysis of the order book, and taking into account the Offer Shares that must be allocated to the Cornerstone Investors. Provided that there is sufficient demand, it is intended that at least 10% of the Offer Shares will be allocated to retail investors in the Netherlands and Belgium. The proportion of Offer Shares allocated to retail investors in the Netherlands and Belgium may be increased or reduced if applications received from them exceed or do not reach, respectively, 10% of the Offer Shares. Retail investors in Belgium and the Netherlands will be treated equally in terms of allocation in case of an oversubscription of the Offering. In case of oversubscription of the Offer Shares reserved for retail investors, the allocation to retail investors will be made on the basis of objective allocation criteria, such as the number of Offer Shares for which applications are submitted by retail investors. The allocation for retail investors will be publishedin a company press release that will also be posted on the Company's website.
SETTLEMENT DATE	The settlement date (the "Settlement Date") is expected to be on or about 16 March 2017 unless the Offering Period is closed earlier or extended..
LISTING	On the regulated markets of Euronext Amsterdam and Euronext Brussels.
DIVIDEND POLICY	The Company has not paid any dividends since its incorporation and it does not expect to pay dividends in the foreseeable future.
USE OF PROCEEDS	The Company will receive only the proceeds of the Offering resulting from the issuance of the New Offer Shares. The Company will not receive any proceeds from the sale of the Management Shares by the Avantium Foundation on behalf of the CEO, CFO and CTO. If the Offering is fully subscribed at the Offer Price, the gross proceeds from the Offering for the company are estimated to be approximately EUR 89.5 million or, in case of exercise in full of the Increase Option and the Over-Allotment Option, be approximately EUR 118.3 million. Costs of the Company associated with the Offering are expected to total up to approximately €8.0 million (including all estimated expenses relating to the Offering and payment in full of all fees and commissions payable to the Syndicate relating to the Offering including the discretionairy fee with a maximum of 1% of the price equivalent of the Offer). The minimum net proceeds of the Offering for the Company must be at least €[65] million. The Company currently anticipates that it will use the net proceeds of the Offering as follows: (i) approximately €65-75 million of the net proceeds will be used to fund the Joint Venture enabling it to construct and operate the Reference Plant for the commercialisation of the YXY Technology;

	(ii) approximately €15-20 million of the net proceeds will be used to build pilot plants for the two most advanced development projects in the Renewable Chemistries business, Project Zambezi and Project Mekong and to operate these plants up to commercial stage (approximately €7.5-10 million for each project); and (iii) the remainder will be used for other projects in Renewable Chemistries (including project Volta) and general corporate purposes in line with the Group's business and strategy, such as working capital and (re-)financing needs, general and administrative expenses, and additional costs associated with being a public company. If the net proceeds of the Offering amount to €65 million, the Company anticipates that it will use the entire amount for the funding of the Joint Venture. The funding of the Joint Venture referred to under (i) above will only arise following FID (i.e. the formal approval for the construction of the Reference Plant and approval of the associated capital expenditures), which is aimed to be taken in the fourth quarter of 2018. If the Reference Plant will not be built in accordance with the terms of the Joint Venture Agreement, the Management Board will, following approval by the Supervisory Board and the General Meeting, resolve on an alternative use of the net proceeds referred to above under (i).
INVESTMENT OBJECTIVE	A share has an unlimited maturity and does not offer any scheduled repayment of the capital. These shares are expected to trade on the regulated market of Euronext Amsterdam and Euronext Brussels, which may lead to capital gains or losses. These shares may be entitled to dividends (although this is not the intention in the foreseeable term). In the event of liquidation the shareholder ranks only after all other creditors. Usually shareholders do not recover anything. As a shareholder of the Company your rights will be governed by Dutch law.
DOCUMENTATION	The Prospectus was approved on 6 March 2017 by the Netherlands Authority for the Financial Markets (Stichting Autoriteit Financiële Markten, the AFM) and has been notified to the Belgian Financial Services and Markets Authority (the FSMA) for passporting in accordance with article 18 of the Prospectus Directive. The Prospectus is available in English and the summary of the Prospectus has been translated into Dutch and French. The Prospectus will be made available at no cost at your KBC Bank branch and via the KBC Team at +32 78 152 153. You can also view the Prospectus on the websites of KBC Bank NV and KBC Securities (www.kbc.be/avantium), www.kbcsecurities.be, www.bolero.be, on the website of the Company Avantium (www.avantium.com) and on the website of the FSMA (www.fsma.be).

Risk

REDEMPTION	This investment comprises a share and does not offer any scheduled repayment of capital. Prospective investors must be able to bear the economic risk of an investment in the Offered Shares and should be able to sustain a partial or total loss of their investment.
DIVERSIFICATION	None: investment in a single security
MARKET SENSITIVITY	The stock market price may fluctuate considerably over time depending on how the business develops, the sector in which the business operates, movements on the financial markets and other macroeconomic conditions.
RISKS RELATING TO THE COMPANY'S INDUSTRY AND BUSINESS	The following is a selection of key risks that relate to the Group's industry, business and operations, the establishment of the Company as a publicly listed company and the Offering. In making the selection, the Group has considered circumstances such as the probability of the risk materialising on the basis of the current state of affairs, the potential impact which the materialisation of the risk could have on the Group's business, financial condition and results of operations. Investors should read, understand and consider all risk factors, set out in Chapter 4 "Risk Factors" beginning on page 52 of the Prospectus before making an investment decision to invest in the Offer Shares. **Risks relating to the Group's business and industry** (i) The Group has incurred losses and negative operating cash flow and has an accumulated deficit. The Group anticipates that it will continue to incur losses for the foreseeable future and the Group may never achieve or sustain profitability; (ii) The Group's ability to generate profits from the YXY Technology depends mainly on the Joint Venture being able to successfully commercialise this technology;

	(iii) The Group may not be able to successfully develop its R&D projects in the Renewable Chemistries business, which may adversely affect the Group's business, financial condition, result of operations and prospects; (iv) In order to further develop or to commercialise its R&D projects in the Renewable Chemistries business, collaboration with partners may be necessary. If the Group fails to enter into, maintain or successfully execute joint development agreements with partners for its R&D projects in the Renewable Chemistries business, it may not be able to develop and commercialise these projects; (v) The Group could face technology scale-up challenges in its Renewable Chemistries business which could delay or prevent the further development and commercialisation of its projects; (vi) The Group's revenues from its Catalysis business are, for a large part, generated from a small number of large customers; and (vii) If the Group is unable to adequately protect its proprietary technology, products and processes, information, trade secrets and know-how this could have a material adverse effect on its business. **Risks relating to the Joint Venture** (viii) The decision to proceed with the construction of the Reference Plant is subject to certain conditions and each of Avantium and BASF may exercise its exit right resulting in a winding up of the Joint Venture prior to a positive decision to construct the Reference Plant. No assurance can be given that the Reference Plant will be completed on schedule or within budget, or at all. (ix) The Group does not control the Joint Venture and the interests of BASF may conflict with the interests of the Group which may have an adverse impact on the value of the Joint Venture; and (x) The commercial success of the Joint Venture will depend on the market acceptance of PEF and PEF products and the Joint Venture's ability to sell FDCA, PEF and Licences, which may only become clear once the Reference Plant becomes operational; and (xi) The YXY Technology may not perform as expected at the planned scale at the Reference Plant and FDCA produced at the Reference Plant or PEF produced by third parties may not meet the required product quality standards or specifications. (xii) Litigation or third party claims of intellectual property infringement could require substantial time and money to resolve and may result in liability for damage. Unfavourable outcomes in these proceedings could limit the Joint Venture's intellectual property rights and could prevent it from commercialising the YXY Technology.
RISKS RELATED TO THE SHARES AND THE OFFERING	(i) Following the Offering, the Company's largest Shareholders will be in a position to exert substantial influence on the Company and the interests pursued by these Shareholders could differ from the interests of the Company's other Shareholders; (ii) There is a risk that an active and liquid market for the Shares will not develop and the price of the Shares may be volatile; (iii) Fluctuations in revenues and other income generated by the Joint Venture can have a material impact and may lead to volatility of the Group's share price; and (iv) The Company does not intend to pay dividends for the foreseeable future and its ability to pay dividends in the foreseeable future is uncertain. These and the other risks related to the shares and the Offering are described in more detail in section "Risk Factors" of the Prospectus (pp. 52 – 68).
FURTHER INFORMATION	Investors who want detailed information on the risk factors should read the Prospectus carefully, paying particular attention to the "Risk Factors" section.

Product rating

PRODUCT RATING	**7** on a scale of 1 (low risk) to 7 (high risk). If estimates of the factors used to determine product ratings change owing to market circumstances, the product rating can also change. Investors will be informed through the usual communication channels of any change in the risk profile (a product rating of 1 corresponds with a highly defensive risk profile, a product rating of 2-3 with a defensive profile, a product rating of 4-5 with a dynamic profile and a product rating of 6-7 with a highly dynamic profile). For more information and background on the various factors used to determine the product ratings see www.kbc.be/productrating

Charges

SUBSCRIPTION CHARGES	None
COSTS RELATING TO THE OFFERING	Costs of the Company associated with the Offering are expected to total up to approximately €8.0 million (including all estimated expenses relating to the Offering and payment in full of all fees and commissions payable to the Syndicate relating to the Offering including the discretionairy fee with a maximum of 1% of the price equivalent of the Offer Shares). The fees and commissions payable to the Syndicate by the Company are expected to amount to approximately €3.6 assuming a full placement of the New Offer Shares at the Offer Price (not including the discretionary fee mentioned above). KBC Securities will receive ca. 36% of the fees and commissions payable to the Syndicate (excluding the discretionary fee).
CUSTODY FEE	Charges for holding the shares in custody account: to be borne by the subscriber (see Schedule of Rates and Charges).
FINANCIAL SERVICES	Free of charge at KBC Bank NV (see Schedule of Rates and Charges).
SCHEDULE OF RATES AND CHARGES	All rates and charges applying at KBC Bank NV can be found at http://kbc-pdf.kbc.be/vermogensopbouw/tarieven_effecten_en.pdf

Liquidity

INITIAL LISTING	Trading of the shares is expected to commence on or about 15 March 2017 (unless in case of extension of the Offering Period) on the regulated markets of Euronext Brussels and Euronext Amsterdam.
NEGOTIABILITY	Daily.

Tax treatment

GENERAL	The tax treatment will depend on each investor's individual circumstances and may change in the future. The general principles are set out in the section "Taxation in Belgium" of the Prospectus.
TAX ON STOCK MARKET TRANSACTIONS	Tax on buy or sell transactions on the secondary market: 0.27% of the transaction value, with a maximum of EUR 1.600 per transaction and per party.
TAX TREATMENT IN BELGIUM	Dividends are currently (i.e. on the date of this product info sheet) subject to withholding tax at the rate of 30% on the gross amount. The withholding tax constitutes the final tax for Belgian individuals, which means that any income from the shares does not have to be declared in their annual tax return.

Glossary

For an overview of financial and economic terms, go to **www.kbc.be/lexicon** (available in Dutch and French)

Contact: KBC-Team
Tel: 016 43 29 15
Website: www.kbc.be/ask-your-question

This product info sheet contains only marketing information. It does not contain any investment advice or investment research, just a summary of the product's features. The information is valid on the date of the product sheet, but could change in the future. Should this information change prior to trading on the regulated market of Euronext Brussels and Euronext Amsterdam, KBC Bank NV will inform the investor appropriately. Detailed information on this product, the relevant terms and conditions and the associated risks can be found in the Prospectus, which can be obtained from your KBC Bank branch or viewed at www.kbc.be/aandelentransacties or http://www.avantium.com. This product info sheet is governed by the laws of Belgium and is subject to the exclusive jurisdiction of the Belgian courts. Any complaints can be addressed internally to klachten@kbc.be and/or 0800 62 084 and/or externally to ombudsman@ombudsfin.be.

Publisher: KBC Bank NV, Havenlaan 2, 1080 Brussels, Belgium VAT BE 0462.920.226, RLP Brussels

Bank & Verzekering